About
Contact & Profiles
A5014780707
Research Areas
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
Central Clinical Hospital and Polyclinic
2021
The study objective is to evaluate effectiveness and tolerability of 1st line combination immuno-oncological therapy with nivolumab ipilimumab in patients metastatic renal cell carcinoma (mRCC) clinical practice. Materials methods. included 38 mRCC who received immunotherapy between July 2019 September 2021. Median follow-up duration was 8 (2-25) months. Mean age the 58.3 (20-85) years. Previously 22 (57.9 %) underwent surgical treatment. Unfavorable physical status 2-3 per ECOG scale...
10.17650/1726-9776-2021-17-3-47-63
article
EN
Cancer Urology
2021-11-11
Coming Soon ...